GlassScriptPhysician profile
Jimmy Wu
NPI 1982647939
$17,036.22
in general payments reported to CMS, 2019-2025
29 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,875 · 2020: $1,060 · 2021: $2,345 · 2022: $2,478 · 2023: $3,017 · 2024: $2,775 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,278.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,554.55 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $2,026.85 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,699.96 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $1,351.56 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $1,337.28 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $1,144.00 | 2021-2025 | |
| Lilly USA, LLC | $943.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $823.48 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $754.94 | 2019-2022 | |
| Gilead Sciences, INC. | $630.80 | 2019-2024 | Vemlidy |
| Janssen Pharmaceuticals, INC | $599.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $523.30 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Teva Pharmaceuticals USA, INC. | $423.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $366.52 | 2019-2025 | |
| Pfizer INC. | $351.84 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $223.12 | 2024-2025 | |
| Ardelyx, INC. | $207.49 | 2024-2025 | Ibsrela |
| Amgen INC. | $181.15 | 2023-2025 | Repatha, Otezla, Repatha |
| Corcept Therapeutics | $167.34 | 2023-2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $162.08 | 2024-2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $143.27 | 2022 | |
| Aimmune Therapeutics, INC. | $124.98 | 2024 | |
| Nestle Healthcare Nutrition INC. | $94.95 | 2021-2022 | |
| Sanofi Pasteur INC. | $82.54 | 2022-2024 | |
| Allergan, INC. | $28.45 | 2019-2020 | |
| Radius Health, INC. | $26.50 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.49 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.37 | 2022 | |
| Cranial Technologies, INC | $18.76 | 2023 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.